Oncternal Therapeutics, Inc.

NasdaqCM:ONCT Rapporto sulle azioni

Cap. di mercato: US$12.8m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Oncternal Therapeutics Crescita futura

Future criteri di controllo 0/6

Si prevede che i ricavi e gli utili di Oncternal Therapeutics diminuiranno rispettivamente del 55.1% e 16.3% all'anno, mentre si prevede che l'EPS crescerà del 18.4% all'anno.

Informazioni chiave

-16.3%

Tasso di crescita degli utili

18.4%

Tasso di crescita dell'EPS

Biotechs crescita degli utili30.3%
Tasso di crescita dei ricavi-55.1%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento09 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Jun 14
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Mar 03
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Nov 06
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Jul 12
Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Jan 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct 03

Oncternal Therapeutics begins phase 3 study of zilovertamab

Sep 27

Oncternal Therapeutics: Selling For Under Cash Value

Sep 02

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Aug 09

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Aug 07
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

Jul 14

Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve

Jun 07

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Apr 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Oncternal Therapeutics: Trading Near Cash With Impressive Results

Jan 04

Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Nov 09
Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company

Oct 10

Oncternal: Solid Data In 2 Cancers With High Unmet Need

Jun 17

We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

May 05
We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Mar 01
Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:ONCT - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20251-45N/AN/A2
12/31/20242-36N/AN/A3
6/30/20242-36-25-25N/A
3/31/20241-36-29-29N/A
12/31/20231-39-32-32N/A
9/30/20231-42-35-35N/A
6/30/20231-43-41-41N/A
3/31/20231-46-39-39N/A
12/31/20221-44-37-37N/A
9/30/20222-41-34-34N/A
6/30/20224-39-29-29N/A
3/31/20224-35-29-29N/A
12/31/20214-31-27-27N/A
9/30/20215-26-24-24N/A
6/30/20214-21-23-23N/A
3/31/20214-18-19-19N/A
12/31/20203-17-17-17N/A
9/30/20203-19-17-17N/A
6/30/20202-19-15-15N/A
3/31/20203-37-17-17N/A
12/31/20192-34-17-17N/A
9/30/20192-31-16-16N/A
6/30/20192-28-12-12N/A
3/31/20193-7-7-7N/A
12/31/20183-7-7-7N/A
12/31/20172-10N/A-9N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ONCT rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ONCT rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ONCT rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di ONCT diminuiranno nei prossimi 3 anni ( -55.1% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di ONCT diminuiranno nei prossimi 3 anni ( -55.1% all'anno).


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ONCT è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita